Revenue associated with our legacy medical device performance Avid SurVeil license fee revenue is expected to range from $29,500,000 to $30,000,000 which includes approximately 25,000,000 revenue recognized in fiscal 2023 on the $27,000,000 PMA milestone payment. This assumes 4th quarter revenue associated with the CMA milestone of $400,000 In the prior year, total Avid SurVeil license fee revenue was 5,700,000 Our updated diluted loss per share guidance reflects the following full year assumptions. Product gross margin in the high 50s, reflecting continuing mix impact from growth in device sales during the manufacturing scale up phase. R and D expense in the range $48,500,000 to $49,000,000 and SG and A expense of $52,500,000 to 53,000,000 Interest expense of approximately $3,400,000 Finally, our updated EPS guidance reflects full year tax of $4,000,000 to $5,000,000 This assumes a sizable tax benefit in the 4th quarter of approximately 8.5 to $9,500,000 Lastly, with respect to cash utilization, we anticipate that we will finish the fiscal year with approximately $37,500,000 to $38,000,000 of cash, with cash used in the Q4 of approximately $6,500,000 to 7,000,000 which includes approximately $3,000,000 in estimated cash tax obligations as a result of the PMA milestone payment. This reflects our disciplined expense management, the spending reduction plan implemented in the Q2 and our active management of working capital.